Dose and frequency titration of somatostatin analogues in the treatment of acromegaly – an injection of expediency?

This publication has 11 references indexed in Scilit:

• Optimal dosage interval for depot somatostatin analogue therapy in acromegaly requires individual titration
  Clinical Endocrinology, 2000
• Lanreotide 60 mg, a Longer-Acting Somatostatin Analog: Tumor Shrinkage and Hormonal Normalization in Acromegaly
  Pituitary, 2000
• Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly
  Clinical Endocrinology, 2000
• Long-Acting Octreotide LAR Compared with Lanreotide SR in the Treatment of Acromegaly
  Pituitary, 2000
• In vitro and in vivo evaluation of a somatostatin analogue released from PLGA microspheres
  Journal of Controlled Release, 2000
• Treatment of Acromegaly with the Growth Hormone–Receptor Antagonist Pegvisomant
  New England Journal of Medicine, 2000
• Octreotide as Primary Therapy for Acromegaly
  The Journal of Clinical Endocrinology & Metabolism, 1998
• A comparison of octreotide delivered by continuous subcutaneous infusion with intermittent injection in the treatment of acromegaly
  European Journal of Clinical Investigation, 1992
• SMS 201–995: A very potent and selective octapeptide analogue of somatostatin with prolonged action
  Life Sciences, 1982
• ACTION OF GROWTH-HORMONE-RELEASE INHIBITORY HORMONE IN HEALTHY MEN AND IN ACROMEGALY
  The Lancet, 1973